Expression and function analysis of dengue virus type 1 to 4 envelope domain Ⅲ recombinant fusion protein

Objecfive To observe the ability of dengue virus type 1-4 envelope domain Ⅲ fusion protein to inhibit virus infection and analyze the neutralizing ability of polyclonal antibodies against rEⅢ.Methods After being connected by linker peptide.EⅢ protein of Dengue virus serotypes 1-4 were expressed in E coli BL21(DE3) then purified.Fusion proteins were verified by Western Blot and ELISA.Rabbits were immunized with fusion proteins to produce anti-rE Ⅲ serum.The activity of anti-rEⅢ serum were detected through indirect immunofluorescence assay test.Inhibition of dengue virus type 1 to 4 infection in BHK-21 cells by rEⅢ fusion protein were tested.Neutralizing activity of anti-rEⅢ serum was analyzed.Results Dengue virus type 1 to 4 envelope domain Ⅲ recombinant fusion protein was expressed in Ecoli BL21 and purified successfully.Then rEⅢ fusion protein and anti-rEⅢ serum were analyzed respectively and rEⅢ fusion protein can effectively inhibit dengue virus type 1 to 4 from infecting BHK cells.The anti-rE Ⅲ serums can neutralize dengue virus type 1 to 4 but with different neutralizing titer.Conclusion Dengue virus type 1-4 envelope domain Ⅲ fusion protein can directly inhibit DV infeetion.Antibodies induced by rE Ⅲ fusion proteins can neutralize dengue virus type 1-4.     

登革病毒1～4型E蛋白结构域Ⅲ融合蛋白的表达纯化及功能研究

目的 了解原核表达的登革病毒（Dengue virus,DV）1～4型融合的E蛋白结构域Ⅲ直接抑制登革病毒感染及其抗体的中和作用.方法 通过连接肽将1～4型登革病毒包膜蛋白Ⅲ区串联的基因产物插入PET30a在大肠埃希菌中进行表达、纯化后,应用Western Blot及间接ELISA验证表达产物.将融合蛋白免疫新西兰大白兔制备免疫血清,应用间接免疫荧光检测多抗血清的活性.将融合蛋白及多抗血清分别进行阻断实验和中和实验,对抗原及抗体的功能进行研究.结果 在大肠埃希菌中成功表达了串联的登革病毒1～4型E蛋白结构域Ⅲ融合蛋白,并得到兔抗免疫血清,分别对融合蛋白及兔抗免疫血清进行验证.融合蛋白能够阻断1～4型DV感染,兔抗免疫血清能中和1～4型DV,但中和抗体效价不同.结论 串联表达的登革病毒包膜蛋白Ⅲ区可抑制登革病毒感染,串联rEⅢ蛋白免疫新西兰大白兔产生的针对DV1～4型包膜蛋白结构域Ⅲ区的抗体对登革病毒具有中和作用.     

Cloning and analysis of the envelope protein clone of HIV-1, CHNHLJ03009c34 from an infected individual in Heilongjiang province

Envelopeglycoprotein(Env)ofHIV1isacom plexoftwononcovalentlyassociatedsubunits,Gp120andGp41.Gp120isanexternalsubunit thatbindsthecellularreceptorCD4andachemo kinereceptor,suchasCXCR4orCCR5.Gp41isatransmembranesubunit,responsibleforthere ceptor mediatedmembranefusion[1,2].Because ofthehighvariabilityofHIV1,theaminoacid sequenceaswellasthestructureofviralenvelope canvaryandresultinthechangeofviraltropism withtimeextensionanddiseaseprogressionafter infection.DuringtheearlyphaseofHIVinfec…     

Efficiency of recombinant bacille Calmette-Guérin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice

Purpose

The third variable (V3) loop of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein has been intensively studied for AIDS vaccine development. Bacille Calmette-Guérin (BCG) is widely used to immunize against tuberculosis and has many advantages as a vaccine vehicle, such as low toxicity, adjuvant potential, low cost, and long-lasting immune-inducing capacity. This work was initiated to investigate the immunogenicity of recombinant BCG (rBCG-mV3) designed to express trimeric HIV-1 V3 loop (mV3) in rBCG-mV3-immunized animals.

Materials and Methods

HIV-1 V3-concatamer was cloned into pMV261, a BCG-expression vector, and then rBCG-mV3 was constructed by introducing the recombinant plasmid (pMV-V3). The recombinant BCG was examined with regard to its expression of V3-concatamer and the genetic stability in vivo and in vitro. The immune responses induced by recombinant BCG were tested in immunized mice and guinea pigs.

Results

The rBCG-mV3 expressed detectable amounts of V3-concatamer when induced by single heat-shock. The recombinant BCG was genetically stable and maintained the introduced mV3 gene for several weeks. V3-specific antibodies were clearly detected 6 weeks after inoculation. The antibody titer rapidly increased after immunization up to 10 weeks, and then maintained for over 4 weeks. IgG2a was prevalent in the V3-specific antiserum. The recombinant BCG was also effective in inducing delayed-type hypersensitivity responses in the immunized guinea pigs. rBCG-immunized mice retained substantial amounts of V3-specific T cells in the spleen, even 5 months after the first immunization.

Conclusion

Recombinant BCG-mV3 is very efficient in inducing humoral and long-lasting cell-mediated immunity against HIV-1 V3 in the immunized animals.